Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

CorMedix

Matterport

NRX Pharmaceuticals

Purple Innovation

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Analysts, Targets Up To 353%

Positive trial data is powering the biotech's stock higher today.

Why Adaptimmune Therapeutics Stock Is Glowing Green Today

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Dennis Williams - Senior Vice President, Late Stage Development Jo Brewer - Chief Scientific Officer Helen Tayton-Martin - Chief Business and Strategy Officer Conference Call Participants Marc Frahm - Cowen & Company Tony Butler - Roth Capital Partners Mara Goldstein - Mizuho Jonathan Chang - SVP Securities Peter Lawson - Barclays Soumit Roy - Jones Trading Operator Hello and welcome to Adaptimmune's Third Quarter Call and Business Update. I would now turn the call over to Juli Miller.

Adaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Call Transcript

Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors Adaptimmune will initiate a rolling BLA submission for afami-cel for the treatment of synovial sarcoma in Q4 2022 with target for completion in mid-year 2023 The Company will focus on advancing the SURPASS family of trials in ovarian, urothelial, and head & neck cancers, for which the ORR is now 52% Adaptimmune plans to advance its wholly owned late-stage

Adaptimmune Reports Third-Quarter Financial Results and Business Update

New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4CD8 Across the entire ongoing Phase 1 SURPASS trial, the ORR has increased to 37% from 33%, and the median duration of response has increased to ~20 weeks from ~12 weeks since last update Increased ORR now 43% in ovarian cancer with one new response; Initiating Phase

Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2022, before the US markets open on Tuesday, November 8, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day.

Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022

Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2023 –Adaptimmune will continue to prioritize and focus on its lead MAGE-A4 franchise while determining the optimal development path for complementary PRAME and NY-ESO assets –Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp.

Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc ("Adaptimmune" or the "Company") (NASDAQ: ADAP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Adaptimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adaptimmune Therapeutics plc - ADAP

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development planned in ovarian (SURPASS-3), urothelial, and head & neck cancers -- Across all tumor types in the SURPASS trial, responses observed in five solid tumor types in 43 heavily pre-treated patients with an ORR of 33% -- Across non-sarcoma tumors, significantly higher response rates compared

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial data and outline future plans for the SURPASS family of trials during a live virtual event to be held on Friday, September 9th, at 8 a.m.

Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Tony Butler - Roth Anthony Rodriguez - Cowen & Company Jonathan Chang - SVP Leerink Mara Goldstein - Mizuho Securities Danya Hail - Jones Research Operator Good morning, everyone. Welcome to the Adaptimmune's Q2 Financial and Business Update Conference Call.

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript

- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held today, August 4, 2022, at 8:00 a.m. EDT (1:00 p.m. BST) -Philadelphia, Pennsylvania, and Oxford, United Kingdom--(Newsfile Corp.

Adaptimmune Reports Second-Quarter Financial Results and Business Update

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before the US markets open on Thursday, August 4, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.The press release...

Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

Axsome Therapeutics

G1 Therapeutics

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022.

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Buyout fever is sparking interest in the biotech's beaten-down shares today.

Why Adaptimmune Therapeutics Stock Is Popping Today

Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell that targets the MAGE-A4 CTA and is being tried in multiple tumors types.

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- Responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher MAGE-A4 expression -- Afami-cel demonstrated a favorable benefit:risk profile -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 26, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer,...

Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track

The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro -

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Officer Gavin Wood – Chief Financial Officer Helen Tayton-Martin – Chief Business Officer John Lunger – Chief Patient Supply Officer Elliot Norry – Chief Medical Officer Cintia Piccina – Chief Commercial Officer Conference Call Participants Marc Frahm – Cowen and Company Tony Butler – ROTH Capital Faisal Khurshid – SVB Securities Nick Abbott – Wells Fargo Mara Goldstein – Mizuho Operator Good morning and thank you for standing by. Welcome to the First Quarter 2022 Adaptimmune Earnings Conference Call.

Adaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call Transcript

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.

Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets open on Monday, May 9, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.

Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022

Agenus

Sorrento Therapeutics Inc

Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.

Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today

Investors were not pleased that the company is preparing for a stock sale.

News for Adaptimmune Therapeutics Stock (ADAP)